HoneyBear Biosciences is a Taiwan-based biotechnology company developing next-generation precision oncology therapeutics, antibody-radionuclide conjugates (ARCs). The company’s core platform, CoNectar®, is a proprietary site-specific glycan conjugation technology designed to enable precise payload attachment, controlled drug-to-antibody ratio, and potential multi-payload conjugation. By combining antibody targeting with advanced conjugation chemistry, HoneyBear aims to create differentiated cancer therapies with improved efficacy, stability, and therapeutic window.